Astrazeneca Plc (LON:AZN) has announced its half-year financial report.
Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030
Revenue and EPS summary
| H1 2026 | % Change | Q2 2026 | % Change | |||
| $m | Actual | CER1 | $m | Actual | CER | |
| – Product Sales | 28,896 | 8 | 5 | 14,510 | 5 | 4 |
| – Alliance Revenue | 1,699 | 31 | 29 | 874 | 34 | 33 |
| Product Revenue | 30,595 | 9 | 6 | 15,384 | 6 | 5 |
| Collaboration Revenue | 77 | (6) | (9) | – | n/m | n/m |
| Total Revenue | 30,672 | 9 | 6 | 15,384 | 6 | 5 |
| Reported EPS ($) | 3.60 | 4 | 3 | 1.61 | 2 | (2) |
| Core2 EPS ($) | 5.21 | 12 | 11 | 2.63 | 21 | |
Key performance elements for H1 2026
(Growth numbers at constant exchange rates)
* Total Revenue up 6%, with double-digit growth in Oncology and Rare Disease offsetting headwinds from Farxiga US loss of exclusivity and China volume-based procurement
* Core Operating profit and Core EPS increased 11%
* Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK)
* 30 approvals in major regions since Q4 2025 results
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:
“In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets, including in the US for Baxfendy, our first-in-class medicine for hypertension.
While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks. We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months.
We continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030.”
Guidance
AstraZeneca reconfirms Total Revenue and Core EPS guidance3 for FY 2026 at CER, based on the average foreign exchange rates through 2025.
Total Revenue is expected to increase by a mid-to-high single-digit percentage
Core EPS is expected to increase by a low double-digit percentage
The Core Tax rate is expected to be between 18-22%
If foreign exchange rates for July 2026 to December 2026 were to remain at the average rates seen in June 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact (unchanged) compared to the performance at CER, and Core EPS growth would be broadly similar (unchanged) to the growth at CER.
